Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 6/20 | 0.73 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | SPR | P35270 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.40 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30434377 | 1.00 | F11 (0.73) | F11CA12CA1CA2CA9 | |
| SCHEMBL23898959 | 0.88 | F11 (0.77) | F11CA12CA1CA2CA9 | |
| SCHEMBL30434789 | 0.88 | F11 (0.77) | F11CA12CA1CA2CA9 | |
| SCHEMBL26140287 | 0.85 | F11 (0.56) | F11CA12CA1CA2CA9 | |
| SCHEMBL30434722 | 0.84 | F11 (1.00) | F11CA12CA1CA2CA9 | |
| SCHEMBL23898957 | 0.84 | F11 (1.00) | F11CA12CA1CA2CA9 | |
| SCHEMBL23899095 | 0.84 | F11 (1.00) | F11CA12CA1CA2CA9 | |
| SCHEMBL23898958 | 0.82 | F11 (0.77) | F11 | |
| SCHEMBL23899055 | 0.80 | F11 (0.72) | F11CA12CA1CA2CA9 | |
| SCHEMBL23899096 | 0.78 | F11 (0.69) | F11CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230147170-A1 | FACTOR XI ACTIVATION INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230147170-A1 | FACTOR XI ACTIVATION INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230147170-A1 | FACTOR XI ACTIVATION INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2021202254-A1 | FACTOR XI ACTIVATION INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230147170-A1 | FACTOR XI ACTIVATION INHIBITORS | F11, TFPI, F13B | F11 1/4885CA12 1938/4885CA1 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.